Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,730.00
Bid: 1,729.50
Ask: 1,730.50
Change: 1.50 (0.09%)
Spread: 1.00 (0.058%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: SABMiller Accepts Improved AB InBev Offer

Tue, 13th Oct 2015 09:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.
----------
FTSE 100 - WINNERS
----------
SABMiller, up 9.0% at 3,946.50 pence. The Anglo-South African brewing giant has reached a deal to be acquired by larger rival Anheuser-Busch InBev, which increased its offer to GBP44 per share from GBP43.50 on day previously. A formal offer at that price would value SABMiller at GBP71.28 billion, with the combination of the two companies to create a global beer giant with a roughly GBP280 billion market cap. AB InBev now has until 1700 BST on October 28 to decide whether to make an firm offer or walk away.

GlaxoSmithKline, up 1.0% at 1,318.50 pence. JPMorgan upgraded the pharmaceutical company to Neutral from Underweight, and raised its price target to 1,370 pence from 1,320p.
----------
FTSE 100 - LOSERS
----------
Royal Mail, down 4.3% at 451.90 pence. The UK government said it has sold the majority of its 14% stake in Royal Mail PLC for around GBP591.0 million under an accelerated bookbuilding process announced the previous day. The government sold a 13% stake in Royal Mail, comprising around 130.0 million shares, at a placing price of 455.0 pence per share. The remaining 1% stake, equivalent to about 10.0 million shares, will be "gifted" to Royal Mail employees in the UK, marking the government's final disposal of shares.

Barclays, down 2.9%. The lender reportedly plans to name JPMorgan investment banker Jes Staley as its new chief executive, with confirmation to come in the next two weeks depending on regulatory approval. Such a move would put a high profile investment banker in charge at a time when there are big questions about the role of Barclays' investment banking division. Under the ousted Antony Jenkins, a retail banker, Barclays had set about reducing its overall reliance on the division as a source of earnings.

Glencore, down 5.4%. The commodities trader and mining company was down due to concerns about China's economy health. Anglo American, another miner, was down 3.3% and BHP Billiton down 2.0%. China's exports declined at a moderate pace in September as the devaluation of yuan helped it from falling sharply amid weak global demand. At the same time, imports plunged due to a drop in commodity prices and subdued domestic demand.
----------
FTSE 250 - WINNERS
----------
Bellway, up 3.5%. The housebuilder said it should be able to grow volumes by up to 10% in its current financial year, as it reported a 44% jump in pretax profit to GBP354.2 million in the year ended July 31 and raised its dividend to 77.0 pence from 52.0p.

Michael Page International, up 2.1%. The recruitment consultancy said Non-Executive Chairman Robin Buchanan plans to step down, as it reiterated its expectations for its full year. The company said its gross profit in the third quarter of 2015 rose 4.8% to GBP139.2 million from GBP132.9 million in the previous year. This growth was hit by volatility in foreign exchange rates, and at constant currency gross profit would have risen 10.2%.

Sophos Group, up 3.3% at 232.00 pence. Liberum initiated coverage of the security software and hardware developer at Buy with a 290p price target, saying the company has attractive cash dynamics and expects its earnings before interest, taxes, depreciation and amortisation to more than double over the next five years.
----------
FTSE 250 - LOSERS
----------
Weir Group, down 3.7% at 1,298.00 pence. The engineering company was hit by broker price-target cuts. Morgan Stanley cut its price target on Weir Group to 1,200 pence from 1,360p, and reiterated its Underweight rating. Meanwhile, UBS cut its price target on the company to 1,800p from 2,000p, and reiterated a Buy rating.
----------
MAIN MARKET AND AIM - WINNERS
----------
Flybe Group, up 6.6%. The airline on Tuesday boasted double-digit increases in seat capacity, passenger numbers and revenue in its second quarter, but reported a slight decline in passenger load factor.

Mediazest, up 34%. The audio-visual products company said it has secured new business worth a cumulative GBP1.0 million since announcing full-year results in August. It also had won new clients including Diesel SpA, Molson Coors Brewing Co and the John Lewis Partnership, and signed new business with existing clients, such as Hyundai Motor Co, Adidas AG and the Post Office Ltd.

RWS Holdings, up 18%. The patent translation and search company said it enjoyed a "significant" recovery in the second half of its last financial year, a boost after the flat sales performance in the opening six months of the year. The 2% increase in full-year sales, which reached GBP95.1 million, means the numbers were ahead of market expectations prior to the announcement.
----------
MAIN MARKET AND AIM - LOSERS
----------

Arrow Global, down 9.4% at 246.25 pence. Chief Executive Tom Drury, Chief Financial Officer Robert Memmott and other executives, together with an unnamed institutional investor, sold GBP27.5 million of shares in the debt manager. The 11 million shares were sold at 250 pence apiece overnight Monday to Tuesday. They represent a combined stake of 6.3%.

Galantas Gold Corp, down 14%. The company said that an individual intends to challenge its application for planning permission to allow the company to mine underneath the open pit at the Cavanacaw mine in Northern Ireland.

Auhua Clean Energy, down 14%. Chairman David Sumner has resigned due to "increasing demands on his time from his other business commitments", the company said. Raphael Tham has assumed the role of non-executive chairman. Tham was previously vice-chairman.
----------

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.